protega™

Fibrosis develops after after a patient has had acute rejection that may have caused antibodies to attack the kidney. Currently histology from biopsy is used to risk stratify the degree of fibrosis. Protega™ will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. This can help clinicians determine the appropriate treatment to delay or reduce progressive fibrosis.